Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravagalimab SC PFS in Healthy Adults
NCT06402513Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ravagalimab in ulcerative colitis (UC), Sjogren's syndrome and rheumatoid arthritis (RA), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 71 days, Time to Maximum Observed Plasma Concentration up to 71 days and 6 more. Started Jun 2024; status: completed.
02
Drugs
ravagalimab
03
Conditions
ulcerative colitis (UC)Sjogren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06402513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402513.